Topical treatment of purulent bacterial conjunctivitis caused by moxifloxacin-sensitive strains. Official guidance on the proper use of antibacterial drugs should be taken into account.
Composition:
1 ml of solution contains 5 mg of moxifloxacin hydrochloride.
Action:
Antibiotic from the fluoroquinolone group. It exerts bactericidal action due to the inhibition of DNA gyrase and topoimerase IV. Commonly sensitive strains: Gram-positive aerobic organisms: genusCorynebacterium (includingCorynebacterium diphtheriae), Staphylococcus aureus (sensitive to methicillin),Streptococcus pneumoniae, Streptococcus pyogenes, groupStreptococcus viridans; Gram-negative oxygen microorganisms:Enterobacter cloacae, Haemophilus influenzae, Klebsiella oxytoca, Moraxella catarrhalis, Serratia marcescens; anaerobic microorganisms:Proprionibacterium acnes; other microorganisms:Chlamydia trachomatis. Strains for which acquired resistance may be a problem: Gram-positive oxygen microorganisms:Staphylococcus aureus (resistant to methicillin), coagulase-negative strainsstaphylococcus (resistant to methicillin); Gram-negative oxygen microorganisms:Neisseria gonorrhoeae. Organisms with hereditary resistance:Pseudomonas aeruginosa.
Contraindications:
Hypersensitivity to the active substance, to any of the excipients or to other quinolones.
Precautions:
In the event of an allergic reaction to the preparation, it should be discontinued. Serious, severe hypersensitivity reactions to moxifloxacin or any of the other ingredients may require immediate relief. In clinically justified cases, oxygen should be given and normal respiratory function should be ensured. Prolonged use of the drug may cause excessive growth of non-susceptible organisms, including fungi. In the event of superinfection, discontinue use and initiate appropriate alternative treatment. Due to the limited amount of data on safety and efficacy, the use of the preparation in the treatment of conjunctivitis in newborns is not recommended. The drug should not be used in the prophylaxis or empiric treatment of gonococcal conjunctivitis, including gonococcal conjunctivitis, due to the presence of strainsNeisseria gonorrhoeae resistant to fluoroquinolones. Patients with eye infections caused byN. gonorrhoeae they should be treated properly in general. The use of the drug is not recommended for the treatment of infectionsChlamydia trachomatis in patients under the age of 2 years, because it has not been studied in these patients. Patients older than 2 years with eye infections caused byCh. trachomatis they should be treated properly in general. Newborns with neonatal conjunctivitis should be treated according to their condition, i.e. general treatment in cases caused byCh. trachomatis orN. gonorrhoeae. Patients should be instructed not to use contact lenses when they have subjective and subjective signs of bacterial infection of their eyes.
Pregnancy and lactation:
The preparation can be used during pregnancy and during breastfeeding.
Side effects:
Common: taste disorders, eye pain, eye irritation, dry eye, pruritus of the eye, conjunctival congestion, ocular congestion. Uncommon: hemoglobin decrease, headache, paresthesias, corneal epithelial abnormalities, punctate keratitis, keratoconjunctivitis, conjunctival haemorrhage, conjunctivitis, eye edema, discomfort in the eye, blurred vision, reduced visual acuity, eyelid disease, erythema of the eyelids, abnormal feeling in the eye, feeling of discomfort in the nose, sore throat and larynx, feeling of the presence of a foreign body (in the throat), vomiting, increased ALT activity, increased GGT activity. Not known (after marketing) palpitations, dizziness, internal inflammation of the eye, ulcerative keratitis, corneal erosions, corneal abrasions, increased intraocular pressure, corneal opacity, corneal infiltration, corneal deposits, eye allergy, keratitis , corneal edema,photophobia, corneal disease, blepharitis, eyelid edema, increased tearing, discharge from the eye, feeling of a foreign body in the eyes, nausea, erythema, rash, pruritus. Data from clinical trials of pediatric patients, including newborns, suggest that the type and severity of adverse reactions are similar to those in adults.
Dosage:
Adults: the recommended dose is 1 drop into the affected eye (eyes) 3 times a day. The improvement usually takes place within 5 days, but the treatment should be continued for another 2-3 days. If no improvement is observed within 5 days of starting treatment, the recognition and / or treatment should be reconsidered. The duration of treatment depends on the severity of the disease and the clinical and bacteriological course of the infection. No dosage adjustment is necessary in patients with impaired hepatic and renal function, in elderly patients, and in children and adolescents. To prevent the absorption of drops through the nasal mucosa, especially in newborns and children, it is recommended to close the nasal-lacrimal canal for 2-3 min after applying the drop, by pressing with your fingers. If more than 1 topical application is used, a minimum of 5 minutes should be allowed between each administration.
(C)
